All Things Considered for July 17, 2023 Hear the All Things Considered program for July 17, 2023

All Things Considered

A large study of an experimental Alzheimer's drug made by pharmaceutical company Eli Lilly & Co. appears to slow worsening of the degenerative brain disease. Darron Cummings/AP hide caption

toggle caption
Darron Cummings/AP

Shots - Health News

An experimental Alzheimer's drug outperforms one just approved by the FDA

In a large study, the experimental drug donanemab slowed the progression of Alzheimer's by about 35%. That's slightly better than the drug Leqembi, which was fully approved by the FDA on July 6.

John Kindschuh is now a father of three children. Courtesy of John Kindschuh hide caption

toggle caption
Courtesy of John Kindschuh

My Unsung Hero

John was talking with a fellow patient — who noticed his speech rapidly declining

2 min

John was talking with a fellow patient — who noticed his speech rapidly declining

  • Download
  • <iframe src="https://www.npr.org/player/embed/1187484642/1188183522" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

A large study of an experimental Alzheimer's drug made by pharmaceutical company Eli Lilly & Co. appears to slow worsening of the degenerative brain disease. Darron Cummings/AP hide caption

toggle caption
Darron Cummings/AP

An experimental Alzheimer's drug outperforms one just approved by the FDA

  • Download
  • <iframe src="https://www.npr.org/player/embed/1188075646/1188183570" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

Searching for a song you heard between stories? We've retired music buttons on these pages. Learn more here.

All Things Considered